Log in

NYSE:EBSEmergent Biosolutions Stock Price, Forecast & News

$122.33
-7.86 (-6.04 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$121.19
Now: $122.33
$128.91
50-Day Range
$71.88
MA: $95.01
$130.66
52-Week Range
$39.11
Now: $122.33
$137.61
Volume1.25 million shs
Average Volume663,786 shs
Market Capitalization$6.47 billion
P/E Ratio38.11
Dividend YieldN/A
Beta1.41
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats (PHTs). Its products address PHTs, including chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travelers' diseases; and opioids. The company offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. It also provides NARCAN for the emergency treatment of known or suspected opioid overdose; RSDL (Reactive Skin Decontamination Lotion Kit), a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard for intramuscular self-injection of atropine sulfate and obidoxime chloride. In addition, the company offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for treating botulinum disease; and VIGIV (vaccinia immune globulin intravenous) that addresses complications from smallpox vaccination. Further, it provides NuThrax, an anthrax vaccine; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; ADENOVIRUS 4/7, a live attenuated vaccine; rVSV-Lassa, a vaccine for prevention of Lassa fever; rVSV-Marburg, a vaccine for prevention of Marburg hemorrhagic fever; rVSV-Sudan, vaccine for prevention of Sudan hemorrhagic fever; rVSV-QUAD, a vaccine for prevention of hemorrhagic fever; and rVSV-Ebola, a vaccine for prevention of Ebola hemorrhagic fever. Additionally, the company offers FLU-IGIV to treat Influenza A infection in hospitalized patients; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract manufacturing services to third-party customers. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
Read More
Emergent Biosolutions logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
CUSIP29089Q10
Phone240-631-3200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.11 billion
Cash Flow$4.82 per share
Book Value$21.08 per share

Profitability

Net Income$54.50 million

Miscellaneous

Employees1,834
Market Cap$6.47 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$122.33
-7.86 (-6.04 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EBS News and Ratings via Email

Sign-up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Emergent Biosolutions (NYSE:EBS) Frequently Asked Questions

How has Emergent Biosolutions' stock price been impacted by COVID-19 (Coronavirus)?

Emergent Biosolutions' stock was trading at $53.03 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EBS stock has increased by 130.7% and is now trading at $122.33.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Emergent Biosolutions?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Emergent Biosolutions
.

When is Emergent Biosolutions' next earnings date?

Emergent Biosolutions is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Emergent Biosolutions
.

How were Emergent Biosolutions' earnings last quarter?

Emergent Biosolutions Inc (NYSE:EBS) issued its quarterly earnings results on Thursday, July, 30th. The biopharmaceutical company reported $1.98 EPS for the quarter, beating the Zacks' consensus estimate of $0.53 by $1.45. The biopharmaceutical company had revenue of $394.70 million for the quarter. Emergent Biosolutions had a return on equity of 22.92% and a net margin of 13.52%.
View Emergent Biosolutions' earnings history
.

What guidance has Emergent Biosolutions issued on next quarter's earnings?

Emergent Biosolutions issued an update on its FY 2020 After-Hours earnings guidance on Thursday, July, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.5-1.6 billion, compared to the consensus revenue estimate of $1.39 billion.

What price target have analysts set for EBS?

7 brokerages have issued twelve-month target prices for Emergent Biosolutions' stock. Their forecasts range from $67.00 to $112.00. On average, they expect Emergent Biosolutions' stock price to reach $90.14 in the next twelve months. This suggests that the stock has a possible downside of 26.3%.
View analysts' price targets for Emergent Biosolutions
.

Has Emergent Biosolutions been receiving favorable news coverage?

Media stories about EBS stock have been trending extremely negative recently, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Emergent Biosolutions earned a news impact score of -4.1 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future.
View the latest news about Emergent Biosolutions
.

Who are some of Emergent Biosolutions' key competitors?

What other stocks do shareholders of Emergent Biosolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include NVIDIA (NVDA), Gilead Sciences (GILD), salesforce.com (CRM), Netflix (NFLX), Broadcom (AVGO), Advanced Micro Devices (AMD), Intel (INTC), Johnson & Johnson (JNJ), AbbVie (ABBV) and Alibaba Group (BABA).

Who are Emergent Biosolutions' key executives?

Emergent Biosolutions' management team includes the following people:
  • Mr. Fuad El-Hibri, Founder & Exec. Chairman (Age 61)
  • Mr. Robert G. Kramer Sr., CEO, Pres & Director (Age 62)
  • Mr. Richard S. Lindahl, Exec. VP, CFO & Treasurer (Age 55)
  • Mr. Atul Saran, Exec. VP of Corp. Devel., Gen. Counsel & Corp. Sec. (Age 46)
  • Mr. Adam R. Havey, Exec. VP of Bus. Operations (Age 48)

What is Emergent Biosolutions' stock symbol?

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent Biosolutions' major shareholders?

Emergent Biosolutions' stock is owned by a number of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (16.73%), Goldman Sachs Group Inc. (1.44%), Fisher Asset Management LLC (1.06%), Bank of New York Mellon Corp (1.02%), New York State Common Retirement Fund (0.64%) and Prudential Financial Inc. (0.52%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends for Emergent Biosolutions
.

Which major investors are selling Emergent Biosolutions stock?

EBS stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Goldman Sachs Group Inc., Barclays PLC, Strs Ohio, Prudential Financial Inc., Fisher Asset Management LLC, Peregrine Capital Management LLC, and Dana Investment Advisors Inc.. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey, and Zsolt Harsanyi.
View insider buying and selling activity for Emergent Biosolutions
.

Which major investors are buying Emergent Biosolutions stock?

EBS stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Foundry Partners LLC, UBS Group AG, King Luther Capital Management Corp, Central Bank & Trust Co., Hodges Capital Management Inc., Granite Investment Partners LLC, and Investment House LLC.
View insider buying and selling activity for Emergent Biosolutions
.

How do I buy shares of Emergent Biosolutions?

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Emergent Biosolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $122.33.

How big of a company is Emergent Biosolutions?

Emergent Biosolutions has a market capitalization of $6.47 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis. Emergent Biosolutions employs 1,834 workers across the globe.

What is Emergent Biosolutions' official website?

The official website for Emergent Biosolutions is www.emergentbiosolutions.com.

How can I contact Emergent Biosolutions?

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]

This page was last updated on 8/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.